INMB Logo

INmune Bio, Inc. (INMB) 

NASDAQ
Market Cap
$144.9M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
113 of 776
Rank in Industry
77 of 433

Largest Insider Buys in Sector

INMB Stock Price History Chart

INMB Stock Performance

About INmune Bio, Inc.

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; …

Insider Activity of INmune Bio, Inc.

Over the last 12 months, insiders at INmune Bio, Inc. have bought $951,221 and sold $0 worth of INmune Bio, Inc. stock.

On average, over the past 5 years, insiders at INmune Bio, Inc. have bought $363,274 and sold $1.75M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Moss David J (CFO, Treasurer & Secretary) — $503,769. Juda Scott (director) — $331,297. Tesi Raymond Joseph (President and CEO) — $248,040.

The last purchase of 10,000 shares for transaction amount of $52,868 was made by Moss David J (Chief Financial Officer) on 2024‑09‑30.

List of Insider Buy and Sell Transactions, INmune Bio, Inc.

2024-09-30PurchaseChief Financial Officer
10,000
0.0481%
$5.29$52,868-2.23%
2024-09-12PurchasePresident and CEO
15,380
0.0776%
$6.38$98,048-17.06%
2024-09-12PurchaseChief Financial Officer
7,690
0.0388%
$6.38$49,024-17.06%
2024-06-25Purchasedirector
5,000
0.0257%
$7.27$36,350-13.99%
2024-04-19PurchasePresident and CEO
18,028
0.0984%
$8.32$149,993-9.68%
2024-04-19PurchaseChief Scientific Officer
14,423
0.0788%
$8.32$119,999-9.68%
2024-04-19PurchaseCFO, Treasurer & Secretary
18,028
0.0984%
$8.32$149,993-9.68%
2024-04-19Purchasedirector
29,603
0.1617%
$8.32$246,297-9.68%
2023-11-10Purchasedirector
7,000
0.0391%
$6.95$48,650+46.60%
2023-07-12Saledirector
10,000
0.061%
$11.01$110,085-4.75%
2023-03-17PurchaseCFO, Treasurer & Secretary
2,500
0.0136%
$6.42$16,063+27.36%
2022-05-26PurchasePresident and CEO
6,300
0.0355%
$6.41$40,383+21.33%
2022-05-26PurchaseCFO, Treasurer & Secretary
7,700
0.0425%
$6.27$48,279+21.33%
2021-11-17Purchasedirector
2,500
0.0147%
$13.55$33,875-37.24%
2021-11-03SalePresident and CEO
3,626
0.0214%
$20.00$72,520-56.78%
2021-11-03SaleChief Scientific Officer
701
0.0041%
$20.00$14,020-56.78%
2021-11-03SaleCFO, Treasurer & Secretary
1,025
0.0061%
$20.00$20,500-56.78%
2021-10-27SalePresident and CEO
6,517
0.0381%
$20.00$130,340-56.13%
2021-10-27SaleChief Scientific Officer
2,357
0.0138%
$20.00$47,140-56.13%
2021-10-27SaleCFO, Treasurer & Secretary
2,079
0.0122%
$20.00$41,580-56.13%

Insider Historical Profitability

<0.0001%
Tesi Raymond JosephPresident and CEO
1554106
7.0092%
$6.5474<0.0001%
Lowdell Mark WilliamChief Scientific Officer
1510806
6.8139%
$6.5424<0.0001%
Moss David JChief Financial Officer
1285869
5.7994%
$6.5484<0.0001%
Juda Scottdirector
71603
0.3229%
$6.5460<0.0001%
Powers Linda Fdirector
210000
0.9471%
$6.5421<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$6.36M2.74541,3290%+$0<0.0001
BlackRock$2.82M1.21240,166-6.89%-$208,715.36<0.0001
MAI Capital Management, LLC$2.13M0.92181,410+85.09%+$979,926.730.02
RHENMAN & PARTNERS ASSET MANAGEMENT AB$2.09M0.9178,2840%+$00.2
Geode Capital Management$2.01M0.86170,802+0.45%+$8,955.09<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.